This article is more than 5 years old. Information may no longer be current.

Cetuximab plus chemoradiation failed to improve OS in esophageal cancer

Issue: June 25, 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — The addition of cetuximab to chemotherapy and radiation did not extend OS in patients with non-operative esophageal carcinoma, according to results of a phase 3 study presented at the 2014 ASCO Annual Meeting.

David H. Ilson, MD, PhD, a medical oncologist with Memorial Sloan Kettering Cancer Center’s Gastrointestinal Oncology Service and a HemOnc Today editorial board member, and colleagues evaluated data from 328 patients with biopsy-proven squamous cell (n=125) or adenocarcinoma (n=203) of the esophagus. Eighty percent of patients had T3/T4 disease, 66% had N1 disease and 19% had celiac nodal involvement.

 

David H. Ilson

All patients received 50 mg/m² cisplatin and 25 mg/m² paclitaxel concurrently for 6 weeks, as well as daily radiation in 1.8 Gy fractions totaling 50.4 Gy.

Ilson and colleagues randomly assigned patients to cetuximab (Erbitux; Bristol-Myers Squibb, Eli Lilly) or no cetuximab. Those in the cetuximab arm received 400 mg/m² on day 1 followed by 250 mg/m² weekly for 6 weeks.

OS served as the primary endpoint. Median follow-up was 15.4 months.

Overall, the confirmed complete response rate was similar among patients who did and did not receive cetuximab (56% vs. 59%; P=.72). Researchers observed no differences in response based on histology.

The rates of 12-month OS (79% vs. 53%) and 24-month OS (58% vs. 30%; P˂.0001 for both) were significantly higher among patients who achieved complete response than those who had residual disease.

Outcomes did not vary based on treatment assignment. Researchers reported comparable 12-month OS (64% for cetuximab vs. 65% for no cetuximab) and 24-month OS (44% vs. 42%; P=.7 for both) between study arms.

Researchers also observed no survival differences based on histology. Among patients with adenocarcinoma, 12-month OS was 65% for cetuximab vs. 64% for no cetuximab, and 24-month OS was 43% for cetuximab vs. 41% for no cetuximab (P=.37). Among patients with squamous cell histology, 12-month OS was 62% for cetuximab vs. 67% for no cetuximab, and 24-month OS was 46% for cetuximab vs. 43% for no cetuximab (P=.97).

More patients assigned cetuximab experienced a treatment-related grade 4 to grade 5 adverse event (26% vs. 18%), whereas grade 3 adverse events were more common in patients who did not receive cetuximab (49% vs. 45%).

“These results add to the growing body of literature indicating no benefit for current EGFR-targeted therapies in the treatment of unselected patients with esophageal carcinoma,” Ilson and colleagues concluded.

For more information:

Ilson DH. Abstract #4007. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago.

Disclosure: Ilson reports research funding from Bristol-Myers Squibb. The study was funded in part by Bristol-Myers Squibb and grants from the NCI.